AstraZeneca today announces the sale of its West Chester site in Ohio, US, to National Resilience, Inc. (Resilience), a technology-focused manufacturing company dedicated to broadening access to complex medicines.
AstraZeneca today announced an agreement to acquire Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts) that offer a novel cell therapy approach for targeting cancer.
AstraZeneca will present new data advancing its ambition to redefine care at the 2022 San Antonio Breast Cancer Symposium (SABCS), 6-10 December 2022.
Industry leader in Product Delivery
AstraZeneca’s top three position in the 2022 Access to Medicine Index (AtMI) reflects the Company’s leading work to strengthen global health systems, as well as increase equitable and affordable patient access to life-changing treatments.
Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "We believe it’s vital everyone has access to affordable
Based on DESTINY-Gastric02 which showed AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated clinically meaningful efficacy and DESTINY-Gastric01 which showed improved overall survival compared to chemotherapy.
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the treatment of adult patients wit
Positive opinion based on TOPAZ-1 Phase III trial updated survival results showing Imfinzi combination reduced risk of death by 24% vs. chemotherapy alone.
AstraZeneca’s Imfinzi (durvalumab) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line treatment of adult patients with unresectable or metastatic biliary tract cancer (BTC) in combination with chemot
First PARP inhibitor to demonstrate clinical benefit in combination with a new hormonal agent in this setting.
AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone has been recommended for marketing authorisation in the European Union (EU) for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) for
Additional regulatory milestones demonstrate important progress towards bringing new rare disease medicines to patients in China
AstraZeneca today announced the availability of the first rare disease therapy from Alexion, AstraZeneca’s Rare Disease group, in China. The availability of Soliris (eculizumab) for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolyti
Approval based on POSEIDON Phase III trial results, which showed significant survival benefit with a limited course of Imjudo added to Imfinzi and chemotherapy.
AstraZeneca’s Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) plus platinum-based chemotherapy has been approved in the US for the treatment of adult patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC).
Rekordmånga myndighetsgodkännanden och höjd prognos som underbyggs av starka affärsresultat
Intäkter och vinst per aktie – sammanfattning
Första nio månaderna 2022
Q3 2022
Förändring %
Förändring %
MUSD
Utfall
i fasta valutakurser1
MUSD
Utfall
i fasta valu
First and only rescue medication recommended for US approval that has been shown to reduce severe exacerbations.
The Food and Drug Administration’s (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) has voted 16 to 1 that the data support a favourable benefit risk assessment for the use of PT027 (albuterol/budesonide) for the treatment of asthma in people aged 18 years and older. In a
Results presented at American Heart Association (AHA) Scientific Sessions 2022 and being published in the Journal of the American College of Cardiology.
Clinical benefits were observed within two weeks with Farxiga, highlighting the importance of early treatment initiation.
New findings from a pre-specified analysis of DELIVER Phase III trial data show that AstraZeneca’s Farxig
AstraZeneca (LSE/STO/Nasdaq: AZN) är ett globalt, innovationsdrivet bioläkemedelsföretag med fokus på forskning, utveckling och marknadsföring av receptbelagda läkemedel för sjukdomar inom terapiområdena Onkologi, Sällsynta sjukdomar och Bioläkemedel, inklusive kardiovaskulära sjukdomar, njursjukdomar och metabola sjukdomar (CVRM) samt Andningsvägar och Immunologi. AstraZeneca är baserat i Cambridge i Storbritannien och bedriver verksamhet i över 100 länder. Dess innovativa läkemedel används av miljontals patienter över hela världen.
Astraallén
151 85 Stockholm
